Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 3/2007

01-09-2007 | Review

Regulatory molecules involved in inflammasome formation with special reference to a key mediator protein, ASC

Authors: Shun’ichiro Taniguchi, Junji Sagara

Published in: Seminars in Immunopathology | Issue 3/2007

Login to get access

Abstract

The recent identification of cytosolic pattern recognition receptors (PRRs) with leucine-rich repeats, which recognize pathogen-associated molecular patterns (PAMPs), has been garnering considerable attention. Activated PRRs form molecular complexes called inflammasomes, consisting of related proteins that include procaspase 1[interleukin (IL) 1β converting enzyme (ICE)]. Inflammasomes have been shown to facilitate molecular proximity, stimulate activation of procaspase 1, which consequently produces inflammatory cytokines IL-1β and IL-18 and ultimately lead to the initiation of innate immunity. An adaptor protein, apoptosis-associated speck-like protein containing a CARD (ASC), which recruits PRRs carrying the pyrin homologous domain (PYD) and procaspase 1 through PYD and CARD, respectively, is responsible for the formation of some inflammasomes and also activation of procaspase 1. In this review, our main attention will be directed to PYD region analysis of ASC to understand the interaction between PYD-carrying PRRs and ASC. Taking into consideration the other aspects of the ASC gene in the proapoptotic ability and down-regulation by methylation, the biological function of ASC will be discussed in relation to the epigenetic aspects of infection, inflammation, and cancer.
Literature
1.
2.
Inohara N, Chamaillard M, McDonald C, Nunez G (2005) NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 74:355–383PubMedCrossRef
3.
Ting JP, Kastner DL, Hoffman HM (2006) CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 6:183–195PubMedCrossRef
4.
Philpott DJ, Girardin SE (2004) The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 41:1099–1108PubMedCrossRef
5.
Strober W, Murray PJ, Kitani A, Watanabe T (2006) Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6:9–20PubMedCrossRef
6.
Kufer TA, Fritz JH, Philpott DJ (2005) NACHT-LRR proteins (NLRs) in bacterial infection and immunity. Trends Microbiol 13:381–388PubMedCrossRef
7.
Viala J et al Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nature Immunol 5:1166–1174
8.
Meylan E, Tschopp J, Karin M (2006) Intracellular pattern recognition receptors in the host response. Nature 442:39–44PubMedCrossRef
9.
Martinon F, Burns K, Tschopp J (2002) The nflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1β. Mol Cell 10:417–426PubMedCrossRef
10.
Schmitz J. et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490PubMedCrossRef
11.
Thornberry NA, Molineaux SM (1995) Interleukin-1β converting enzyme: a novel cysteine protease required for IL-1β production and implicated in programmed cell death. Protein Sci 4:3–12PubMedCrossRef
12.
Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nat Genet 29:301–305PubMedCrossRef
13.
McDermott MF, Aksentijevich I (2002) The autoinflammatory syndromes. Curr Opin Allergy Clin Immunol 2:511–516PubMedCrossRef
14.
Feldmann J et al (2002) Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71:198–203PubMedCrossRef
15.
Martinon F, Tschopp J (2004) Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell 117:561–574PubMedCrossRef
16.
Solle M et al (2001) Altered cytokine production in mice lacking P2X7 receptors. J Biol Chem 276:125–132PubMedCrossRef
17.
Perregaux D, Gabel CA (1994) Interleukin-1β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 269:15195–15203PubMed
18.
Walev I, Reske K, Palmer M, Valeva A, Bhakdi S (1995) Potassium-inhibited processing of IL-1β in human monocytes. EMBO J 14:1607–1614PubMed
19.
Gurcel L, Abrami L, Girardin S, Tschopp J, van der Goot FG (2006) Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival. Cell 126:1135–1145PubMedCrossRef
20.
Andrei C et al (2004) Phospholipases C and A2 control lysosome-mediated IL-1β secretion: implications for inflammatory processes. Proc Natl Acad Sci USA 101:9745–9750PubMedCrossRef
21.
Masumoto J, Taniguchi S, Ayukawa K et al (1999) ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem 274(33):835–838
22.
The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90:797–807CrossRef
23.
Masumoto J, Taniguchi S, Sagara J (2001) Pyrin N-terminal homology domain- and caspase recruitment domain-dependent oligomerization of ASC. Biochem Biophys Res Commun 280:652–655PubMedCrossRef
24.
Moriya M, Taniguchi S, Wu P, Liepinsh E, Otting G, Sagara J (2005) Role of charged and hydrophobic residues in the oligomerization of the PYRIN domain of ASC. Biochemistry 44:575–583PubMedCrossRef
25.
Masumoto J, Taniguchi S, Nakayama J et al (2001) Expression of apoptosis-associated speck-like protein containing a caspase recruitment domain, a pyrin N-terminal homology domain-containing protein, in normal human tissues. J Histochem Cytochem 49:1269–1275PubMed
26.
Shiohara M, Taniguchi S, Masumoto J et al (2002) ASC, which is composed of a PYD and a CARD, is up-regulated by inflammation and apoptosis in human neutrophils. Biochem Biophys Res Commun 293:1314–1318PubMedCrossRef
27.
Yamamoto M, Yaginuma K, Tsutsui H et al (2004) ASC is essential for LPS-induced activation of procaspase-1 independently of TLR-associated signal adaptor molecules. Genes Cells 9:1055–1067PubMedCrossRef
28.
Mariathasan S, Newton K, Monack DM et al (2004) Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430:213–218PubMedCrossRef
29.
Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87:2095–2147PubMed
30.
Annand RR et al (1999) Caspase-1 (interleukin-1β-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem J 342:655–665PubMedCrossRef
31.
Saleh M et al (2006) Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 440:1064–1068PubMedCrossRef
32.
Razmara M et al (2002) CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J Biol Chem 277:13952–13958PubMedCrossRef
33.
Aksentijevich I et al (1999) Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet 64:949–962PubMedCrossRef
34.
Chae JJ et al (2003) Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 11:591–604PubMedCrossRef
35.
Inohara N, Nunez G (2003) NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 3(5):371–82 (Review, May)PubMedCrossRef
36.
Chae JJ et al (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci USA 103:9982–9987PubMedCrossRef
37.
Messud-Petit F et al (1998) Serp2, an inhibitor of the interleukin-1β -converting enzyme, is critical in the pathobiology of myxoma virus. J Virol 72:7830–7839PubMed
38.
Johnston JB et al (2005) A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity 23:587–598PubMedCrossRef
39.
Bertin J, DiStefano PS (2000) The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ 7:1273–1274PubMedCrossRef
40.
Fairbrother WJ, Gordon NC, Humke EW, O’Rourke KM, Starovasnik MA, Yin JP, Dixit VM (2001) The PYRIN domain: a member of the death domain-fold superfamily. Protein Sci 10:1911–1918PubMedCrossRef
41.
Pawlowski K, Pio F, Chu Z, Reed JC, Godzik A (2001) PAAD—a new protein domain associated with apoptosis, cancer and autoimmune diseases. Trends Biochem Sci 26:85–87PubMedCrossRef
42.
Staub, E., Dahl, E. and Rosenthal, A. (2001) The DAPIN family: a novel domain links apoptotic and interferon response proteins. Trends Biochem Sci 26:83–85PubMedCrossRef
43.
Xiao T, Towb P, Wasserman SA, Sprang SR (1999) Three-dimensional structure of a complex between the death domains of Pelle and Tube. Cell 99:545–555PubMedCrossRef
44.
Qin H, Srinivasula SM, Wu G, Fernandes-Alnemri T, Alnemri ES, Shi Y (1999) Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1. Nature 399:549–557PubMedCrossRef
45.
Weber CH, Vincenz C (2001) The death domain superfamily: a tale of two interfaces? Trends Biochem Sci 26:475–481PubMedCrossRef
46.
Liepinish E, Barbals R, Dahl E, Sharipo A, Staub E, Otting G (2003) The death-domain fold of the ASC PYRIN domain, presenting a basis for PYRIN/PYRIN recognition. J Mol Biol 332:1155–1163CrossRef
47.
Hiller S, Kohl A, Fiorito F, Herrmann T, Wider G, Tschopp J, Grütter MG, Wüthrich K (2003) NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain. Structure 11:1199–1205PubMedCrossRef
48.
Siegel RM, Martin DA, Zheng L, Ng S, Bertin J, Cohen J, Lenardo MJ (1998) Death-effector filaments: novel cytoplasmic structures that recruit caspases and trigger apoptosis. J Cell Biol 141:1243–1253PubMedCrossRef
49.
Perez D, White E (1998) E1B 19K inhibits Fas-mediated apoptosis through FADD-dependent sequestration of FLICE. J Cell Biol 141:1255–1266PubMedCrossRef
50.
Yan M, Lee J, Schilbach S, Godard A, Dexit V (1999) mE10, a novel caspase recruitment domain-containing proapoptotic molecule. J Biol Chem 274:10287–10292PubMedCrossRef
51.
Guiet C, Vito P (2000) Caspase recruitment domain (CARD)-dependent cytoplasmic filaments mediate Bcl 10-induced NF-κB activation. J Cell Biol 148:1131–1139PubMedCrossRef
52.
Hull KM, Shoham N, Chae JJ, Aksentijevich I, Kastner DL (2003) The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 15:61–69PubMedCrossRef
53.
Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors:intracellular regulatetors of infection and inflammation. Nat Immunol 70:31–40
54.
Conway KE, McConnell BB, Bowring CE, Donald CD, Warren ST, Vertino PM (2000) TMS1, a novel proapoptotic caspase recruitment domain protein, is a target of methylation-induced gene silencing in human breast cancers. Cancer Res 60:6236–42PubMed
55.
Guan X, Sagara J, Yokoyama T et al (2003) ASC/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma. Int J Cancer 107:202–208PubMedCrossRef
56.
Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, Picchi MA, Belinsky SA, Herman JG, Taniguchi S, Baylin SB (2006) Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res 66(12):6210–6218 (Jun 15)PubMedCrossRef
57.
Masumoto J, Dowds TA, Schaner P, Chen FF, Ogura Y, Li M et al (2003) ASC is an activating adaptor for NF-kappa B and caspase-8-dependent apoptosis. Biochem Biophys Res Commun 303:69–73PubMedCrossRef
58.
Ohtsuka T, Ryu H, Minamishima YA et al (2004) ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell Biol 6:121–128PubMedCrossRef
59.
Hasegawa M, Kawase K, Inohara N, Imamura R, Yeh W-C, Kinoshita T, Suda T (2007) Mechanism of ASC-mediated apoptosis:Bid-dependent apoptosis in type II cells. Oncogene 26:1748–1756PubMedCrossRef
60.
Grenier JM et al (2002) Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-κB and caspase-1. FEBS Lett 530:73–78PubMedCrossRef
61.
Wang L et al (2002) PYPAF7, a novel PYRIN-containing Apaf1-like protein that regulates activation of NF-κB and caspase-1-dependent cytokine processing. J Biol Chem 277:29874–29880PubMedCrossRef
62.
Mariathasan S, Weiss DS, Dixit VM, Monack DM (2005) Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. Exp Med 202:1043–1049CrossRef
63.
Gavrilin MA et al (2006) Internalization and phagosome escape required for Francisella to induce human monocyte IL-1β processing and release. Proc Natl Acad Sci USA 103:141–146PubMedCrossRef
64.
Zamboni DS et al (2006) The Birc1e cytosolic patternrecognition receptor contributes to the detection and control of Legionella pneumophila infection. Nature Immunol 7:318–325CrossRef
65.
Ren T, Zamboni DS, Roy CR, Dietrich WF, Vance RE (2006) Flagellin-deficient Legionella mutants evade caspase-1- and Naip5-mediated macrophage immunity. PLoS Pathog 2:e18PubMedCrossRef
66.
Molofsky AB et al (2006) Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection. J Exp Med 203:1093–1104PubMedCrossRef
67.
Mariathasan S. et al (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440:228–232PubMedCrossRef
68.
Kanneganti TD et al (2006) Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440:233–236PubMedCrossRef
69.
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237–241PubMedCrossRef
Metadata
Title
Regulatory molecules involved in inflammasome formation with special reference to a key mediator protein, ASC
Authors
Shun’ichiro Taniguchi
Junji Sagara
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Seminars in Immunopathology / Issue 3/2007
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-007-0082-3

Other articles of this Issue 3/2007

Seminars in Immunopathology 3/2007 Go to the issue

Review

The role of the inflammasome in cellular responses to toxins and bacterial effectors

Review

Strategies that modulate inflammasomes—insights from host–pathogen interactions

Introduction

The NLR-related disorders

Review

Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs

Review

The NLR network and the immunological disease continuum of adaptive and innate immune-mediated inflammation against self

Review

The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits